| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID419986 | Reduction of phosphorylated AKT protein expression in human BT474 cells at 4 times GI50 after 24 hrs by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419989 | Antitumor activity against estrogen receptor and HER2 overexpressing human BT474 cells xenografted in Harlan HsdNpa athymic nude mouse assessed as changed in 100 mm'3 tumor volume at 30 mg/kg, po qd | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419978 | Induction of Hsp72 protein expression in human BT474 cells at 2 times GI50 after 24 hrs by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID420130 | Modulation of p23 protein expression in estrogen receptor and HER2 overexpressing human BT474 cells xenografted in Harlan HsdNpa athymic nude mouse at 30 mg/kg, po qd measured 6 hrs after final dose by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID695364 | Inhibition of HSP90 in human BT474 cells assessed as depletion of pHer2 protein level at 0.1 to 1 uM after 24 hrs by Western blot method | 2012 | Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
| Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. |
| AID419993 | Growth inhibition of human T24 cells after 24 hrs by SRB assay | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419983 | Reduction of HER2 protein expression in human BT474 cells at 4 times GI50 after 24 hrs by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419992 | Growth inhibition of human A375 cells after 24 hrs by SRB assay | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID695367 | Inhibition of HSP90 in human BT474 cells assessed as induction of HSP70 at 0.1 to 1 uM after 24 hrs by Western blot method | 2012 | Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
| Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. |
| AID419984 | Reduction of phosphorylated AKT protein expression in human BT474 cells at 2 times GI50 after 24 hrs by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419781 | Binding affinity to ATP binding site of full length human Hsp90beta after 30 mins by fluorescence polarization assay | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419994 | Growth inhibition of human U87MG cells after 24 hrs by SRB assay | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419956 | Half life in BALB/c mouse at 10 mg/kg, po by LC-MS/MS analysis | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419780 | Growth inhibition of human HCT116 cells after 24 hrs by SRB assay | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419953 | AUC last in BALB/c mouse at 10 mg/kg, po by LC-MS/MS analysis | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419779 | Growth inhibition of human PC3M cells after 24 hrs by SRB assay | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419991 | Toxicity in Harlan HsdNpa athymic nude mouse assessed as survival at 30 mg/kg, po qd | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419778 | Growth inhibition of human BT474 cells after 24 hrs by SRB assay | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID420129 | Modulation of AKT protein expression in estrogen receptor and HER2 overexpressing human BT474 cells xenografted in Harlan HsdNpa athymic nude mouse at 30 mg/kg, po qd measured 6 hrs after final dose by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID695363 | Inhibition of HSP90 in human BT474 cells assessed as depletion of Her2 protein level at 0.1 to 1 uM after 24 hrs by Western blot method | 2012 | Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
| Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. |
| AID420131 | Inhibition of Hsp90 ATPase activity in estrogen receptor and HER2 overexpressing human BT474 cells xenografted in in Harlan HsdNpa athymic nude mouse at 30 mg/kg, po qd | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID695366 | Inhibition of HSP90 in human BT474 cells assessed as depletion of AKT protein level at 0.1 to 1 uM after 24 hrs by Western blot method | 2012 | Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
| Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. |
| AID420128 | Decrease in phosphorylated AKT protein level in estrogen receptor and HER2 overexpressing human BT474 cells xenografted in Harlan HsdNpa athymic nude mouse at 30 mg/kg, po qd measured 6 hrs after final dose by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419980 | Induction of Hsp72 protein expression in human BT474 cells at 4 times GI50 after 24 hrs by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419990 | Toxicity in Harlan HsdNpa athymic nude mouse assessed as change in body weight at 30 mg/kg, po qd | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID695365 | Inhibition of HSP90 in human BT474 cells assessed as depletion of pAKT protein level at 0.1 to 1 uM after 24 hrs by Western blot method | 2012 | Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
| Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. |
| AID419995 | Abrogation of interaction between p23 and Hsp90alpha protein in estrogen receptor and HER2 overexpressing human BT474 cells xenografted in Harlan HsdNpa athymic nude mouse at 30 mg/kg, po qd measured 6 hrs after final dose by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419981 | Reduction of HER2 protein expression in human BT474 cells at 2 times GI50 after 24 hrs by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419954 | Cmax in BALB/c mouse at 10 mg/kg, po by LC-MS/MS analysis | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419988 | Antitumor activity against estrogen receptor and HER2 overexpressing human BT474 cells xenografted in Harlan HsdNpa athymic nude mouse assessed as tumor regression at 30 mg/kg, po qd | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID419955 | Tmax in BALB/c mouse at 10 mg/kg, po by LC-MS/MS analysis | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID420132 | Growth inhibition of human MCF7 cells after 24 hrs by SRB assay | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID420127 | Induction of HER2 protein degradation in estrogen receptor and HER2 overexpressing human BT474 cells xenografted in Harlan HsdNpa athymic nude mouse at 30 mg/kg, po qd measured 6 hrs after final dose by Western immunoblotting | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1799223 | Fluorescence Polarization (FP) Assay from Article 10.1021/jm900357y: \\Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.\\ | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |